Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer

被引:375
作者
Bergamaschi, Anna
Kim, Young H.
Wang, Pei
Sorlie, Therese
Hernandez-Boussard, Tina
Lonning, Per E.
Tibshirani, Robert
Borresen-Dale, Anne-Lise
Pollack, Jonathan R. [1 ]
机构
[1] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA
[2] Norwegian Radium Hosp, Rikshosp, Med Ctr, Inst Canc Res,Dept Genet, N-0310 Oslo, Norway
[3] Stanford Univ, Dept Stat, Stanford, CA 94305 USA
[4] Stanford Univ, Dept Biochem, Stanford, CA 94305 USA
[5] Haukeland Hosp, Dept Med Oncol, N-5021 Bergen, Norway
[6] Univ Oslo, Fac Med, Oslo, Norway
关键词
D O I
10.1002/gcc.20366
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer is a leading cause of cancer-death among women, where the clinicopathological features of tumors are used to prognosticate and guide therapy. DNA copy number alterations (CNAs), which occur frequently in breast cancer and define key pathogenetic events, are also potentially useful prognostic or predictive factors. Here, we report a genome-wide array-based comparative genomic hybridization (array CGH) survey of CNAs in 89 breast tumors from a patient cohort with locally advanced disease. Statistical analysis links distinct cytoband loci harboring CNAs to specific clinicopathological parameters, including tumor grade, estrogen receptor status, presence of TP53 mutation, and overall survival. Notably, distinct spectra of CNAs also underlie the different subtypes of breast cancer recently defined by expression-profiling, implying these subtypes develop along distinct genetic pathways. In addition, higher numbers of gains/losses are associated with the '' basal-like '' tumor subtype, while high-level DNA amplification is more frequent in '' luminal-B '' subtype tumors, suggesting also that distinct mechanisms of genomic instability might underlie their pathogenesis. The identified CNAs may provide a basis for improved patient prognostication, as well as a starting point to define important genes to further our understanding of the pathobiology of breast cancer. This article contains Supplementary Material available at http://www.interscience.wiley.com/jpages/1045-2257/suppmat. (c) 2006 Wiley-Liss, Inc.
引用
收藏
页码:1033 / 1040
页数:8
相关论文
共 38 条
[1]  
Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
[2]   Transcriptional regulation and transformation by MYC proteins [J].
Adhikary, S ;
Eilers, M .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2005, 6 (08) :635-645
[3]   Overview of tyrosine kinase inhibitors in clinical breast cancer [J].
Agrawal, A ;
Gutteridge, E ;
Gee, JMW ;
Nicholson, RI ;
Robertson, JFR .
ENDOCRINE-RELATED CANCER, 2005, 12 :S135-S144
[4]   Prognostic relevance of gene amplifications and coamplifications in breast cancer [J].
Al-Kuraya, K ;
Schraml, P ;
Torhorst, J ;
Tapia, C ;
Zaharieva, B ;
Novotny, H ;
Spichtin, H ;
Maurer, R ;
Mirlacher, M ;
Köchli, O ;
Zuber, M ;
Dieterich, H ;
Mross, F ;
Wilber, K ;
Simon, R ;
Sauter, G .
CANCER RESEARCH, 2004, 64 (23) :8534-8540
[5]   Good Old clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers [J].
Edén, P ;
Ritz, C ;
Rose, C ;
Fernö, M ;
Peterson, C .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (12) :1837-1841
[6]   Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer [J].
Foulkes, WD ;
Stefansson, IM ;
Chappuis, PO ;
Bégin, LR ;
Goffin, JR ;
Wong, N ;
Trudel, M ;
Akslen, LA .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (19) :1482-1485
[7]  
Geisler S, 2003, CLIN CANCER RES, V9, P5582
[8]  
Geisler S, 2001, CANCER RES, V61, P2505
[9]   The Stanford Microarray Database: data access and quality assessment tools [J].
Gollub, J ;
Ball, CA ;
Binkley, G ;
Demeter, J ;
Finkelstein, DB ;
Hebert, JM ;
Hernandez-Boussard, T ;
Jin, H ;
Kaloper, M ;
Matese, JC ;
Schroeder, M ;
Brown, PO ;
Botstein, D ;
Sherlock, G .
NUCLEIC ACIDS RESEARCH, 2003, 31 (01) :94-96
[10]   The future of breast cancer: the role of prognostic factors [J].
Gradishar, WJ .
BREAST CANCER RESEARCH AND TREATMENT, 2005, 89 (Suppl 1) :S17-S26